- Home
- OTLK vs NVNO Comparison
OTLK vs NVNO Comparison
Compare OTLK & NVNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OTLK
- NVNO
- Stock Information
- Founded
- OTLK 2010
- NVNO 1987
- Country
- OTLK United States
- NVNO United States
- Employees
- OTLK N/A
- NVNO N/A
- Industry
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- NVNO Medical/Dental Instruments
- Sector
- OTLK Health Care
- NVNO Health Care
- Exchange
- OTLK Nasdaq
- NVNO Nasdaq
- Market Cap
- OTLK 56.3M
- NVNO 61.9M
- IPO Year
- OTLK 2016
- NVNO N/A
- Fundamental
- Price
- OTLK $1.48
- NVNO $2.79
- Analyst Decision
- OTLK Strong Buy
- NVNO
- Analyst Count
- OTLK 5
- NVNO 0
- Target Price
- OTLK $10.20
- NVNO N/A
- AVG Volume (30 Days)
- OTLK 467.0K
- NVNO 105.1K
- Earning Date
- OTLK 02-14-2025
- NVNO 05-07-2025
- Dividend Yield
- OTLK N/A
- NVNO N/A
- EPS Growth
- OTLK N/A
- NVNO N/A
- EPS
- OTLK N/A
- NVNO N/A
- Revenue
- OTLK N/A
- NVNO N/A
- Revenue This Year
- OTLK N/A
- NVNO N/A
- Revenue Next Year
- OTLK $288.46
- NVNO $409.09
- P/E Ratio
- OTLK N/A
- NVNO N/A
- Revenue Growth
- OTLK N/A
- NVNO N/A
- 52 Week Low
- OTLK $0.87
- NVNO $2.45
- 52 Week High
- OTLK $12.85
- NVNO $6.48
- Technical
- Relative Strength Index (RSI)
- OTLK 41.52
- NVNO 37.45
- Support Level
- OTLK $1.38
- NVNO $2.65
- Resistance Level
- OTLK $1.56
- NVNO $3.36
- Average True Range (ATR)
- OTLK 0.12
- NVNO 0.33
- MACD
- OTLK 0.02
- NVNO -0.07
- Stochastic Oscillator
- OTLK 59.26
- NVNO 13.45
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About NVNO enVVeno Medical Corporation
enVVeno Medical Corp is a medical device company focused on the development of bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. Its product, the VenoValve, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI).